Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin
{"title":"Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.","authors":"Hanlin Zhang, Jia Zhou, Keyun Tang, Xinyi Zhang, Hongzhong Jin","doi":"10.1080/09546634.2025.2460582","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.</p><p><strong>Materials and methods: </strong>We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.</p><p><strong>Results: </strong>In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.</p><p><strong>Conclusions: </strong>This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2460582"},"PeriodicalIF":0.0000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2460582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/16 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This review aims to outline the crucial role of IL-36 signaling in inflammatory skin diseases and summarize the therapeutic potential of spesolimab. Our goal is to provide insights into the off-label applications of spesolimab and future directions for its use in treating other challenging skin diseases.
Materials and methods: We conducted a comprehensive literature search across PubMed, Embase, Web of Science, MEDLINE, Scopus, and the Cochrane Library to identify relevant studies. For RCTs, we additionally searched the ClinicalTrials.gov database.
Results: In this review, we examine its off-label applications for conditions such as palmoplantar pustulosis, acrodermatitis continua of Hallopeau, hidradenitis suppurativa, pyoderma gangrenosum, and acute generalized exanthematous pustulosis. This review also explores the role of IL-36 in the pathophysiology of these disorders and discusses how spesolimab may address the limitations of current therapies for refractory cases. Randomized controlled trials and case reports are summarized to highlight the efficacy and tolerability of spesolimab across various inflammatory skin conditions. We highlight the challenges presented by the absence of standardized treatment guidelines and the need for larger clinical trials.
Conclusions: This review underscores the potential of spesolimab to enhance treatment strategies for inflammatory skin diseases.
目的:本文旨在概述IL-36信号在炎症性皮肤病中的重要作用,并总结司匹利单抗的治疗潜力。我们的目标是为spesolimab的超说明书应用提供见解,并为其在治疗其他挑战性皮肤疾病中的应用提供未来的方向。材料和方法:我们在PubMed、Embase、Web of Science、MEDLINE、Scopus和Cochrane图书馆进行了全面的文献检索,以确定相关研究。对于随机对照试验,我们还检索了ClinicalTrials.gov数据库。结果:在这篇综述中,我们研究了它在治疗掌足底脓疱病、持续的埃洛珀肢端皮炎、化脓性汗腺炎、坏疽性脓皮病和急性全发性脓疱病等疾病中的适应症外应用。这篇综述还探讨了IL-36在这些疾病的病理生理中的作用,并讨论了spesolimab如何解决当前治疗难治性病例的局限性。本文总结了随机对照试验和病例报告,以强调司匹利单抗在各种炎症性皮肤状况下的疗效和耐受性。我们强调了缺乏标准化治疗指南和需要更大规模的临床试验所带来的挑战。结论:本综述强调了司匹利单抗增强炎性皮肤病治疗策略的潜力。